Lower selenium levels have been associated with increased risk of prostate cancer (PCa), and genetic variation in the selenoprotein genes selenoprotein P (SEPP1) and glutathione peroxidase 1 (GPX1) is thought to modify this relationship. We investigated whether the association between toenail selenium levels and advanced PCa risk in the prospective Netherlands Cohort Study is modified by common genetic variation in SEPP1 and GPX1. Toenail clippings were used to determine selenium levels and to isolate DNA for genotyping. This case-cohort study, which included 817 case subjects with advanced PCa and 1048 subcohort members, was analyzed with Cox regression models. All statistical tests were two-sided. Three genetic variants were associated with advanced (stage III/IV or IV) PCa risk: SEPP1 rs7579 (lower risk; P trend = .01), GPX1 rs17650792 (higher risk; P trend = .03), and GPX1 rs1800668 (lower risk; P trend = .005). Toenail selenium levels were inversely associated with advanced PCa risk, independently of common genetic variation in SEPP1 and GPX1.
The micronutrient selenium is a key component of selenoproteins that have important biological activities (1) . Lower selenium levels have repeatedly been associated with an increased PCa risk (2) (3) (4) . However, some large epidemiological studies (2) , including the Selenium and Vitamin E Cancer Prevention Trial (SELECT) (5), do not support this inverse relationship. As a result of these disparate findings, it has been hypothesized that the effect of selenium on PCa is modified by selenoprotein gene variation (3, (6) (7) (8) .
Plausible candidate selenoprotein genes to genetically modify the selenium-PCa association are selenoprotein P (SEPP1) and glutathione peroxidase 1 (GPX1). Genetic variants in both genes have previously been identified as having an effect on PCa risk (7, 9) . Furthermore, these genes have known essential biological functions: SEPP1 is involved in selenium transport (10) , and GPX1 counteracts oxidative stress (11) .
We investigated common SEPP1 and GPX1 variation in relation to advanced PCa risk and examined potential interactions with selenium levels measured in toenail samples. In a previous report, based on the same study population, we showed that men in the highest vs lowest toenail selenium quintile had a greater than 60% reduced risk of advanced PCa (12) .
The Netherlands Cohort Study included 58 279 men, aged 55 to 69 years at baseline in 1986 (13). Approximately 81% of participants provided toenail clippings, which were used to determine selenium levels and to extract DNA. Cancer case patients were identified during 17.3 years of follow-up by annual record linkage to cancer registries (14) . Advanced PCa was defined as T3 or T4, N+, or M1 at diagnosis [International Union Against Cancer stage III/IV (15)] (n = 1290). Stage IV PCa was defined as stage T4, N+, or M1 at diagnosis (n = 817). The study had a case-cohort design, and a flow diagram of study participants is shown in Supplementary Figure 1 (available online). The study was approved by the institutional review boards of the Dutch Organization for Applied Scientific Research (TNO) and Maastricht University. Study participants gave informed consent.
Tagging single nucleotide polymorphisms (SNPs) were identified using the HapMap CEU population and parameters of r 2 greater than or equal to 0.8 and minor allele frequency greater than or equal to 10% (16) . SNPs were selected within genes and 5000 base pairs upstream and downstream. We identified five tagging SNPs in SEPP1 and three in GPX1. DNA was extracted from toenails as described previously (17) . DNA was successfully isolated for 1030 case patients and 1885 subcohort members (>99.9% successful DNA isolation). Genotyping was done using Sequenom's MassARRAY software (version 4.0) and iPLEX Gold system (Sequenom, Hamburg, Germany). Quality control included genotyping of blind duplicate samples, which revealed greater than 99% agreement on genotyping calls. Samples with a sample call rate of less than 95% were excluded, and a total of 952 case patients and 1798 subcohort members had complete genotyping data. Most SNPs had greater than 99% genotype completion rates, with the exception of rs230819 (85.7%). None of the SNPs violated Hardy-Weinberg equilibrium (P >.05).
Selenium concentrations were measured in toenails using instrumental neutron activation analysis (12) . For the gene-environment interaction analysis, we used a smaller subset of the subcohort (70%) (18); 817 case patients and 1048 subcohort members had complete genotyping and toenail selenium data.
Age-adjusted Cox proportional hazards regression models were used. The proportional hazards assumption was tested using the scaled Schoenfeld residuals (19) , and we found no violation of the assumption. SNPs were analyzed under a codominant and log-additive genetic model. Standard errors were estimated using the robust Huber-White sandwich estimator (20, 21 || SEPP1 rs230813 and rs230819 were in moderate linkage disequilibrium (r 2 = 0.76).
toenail selenium and genotype (dominant model) were tested using cross-product terms and the Wald test. Selenium quartiles were based on the distribution in the subcohort. Interaction models were adjusted for age, first-degree family history of PCa, smoking status, and duration and frequency of smoking, as described previously (12) . Several other potential confounders were considered (12) , but none of these were selected as they had little effect on the effect estimates (<5%) or precision. All statistical tests were two-sided, with P < .05 considered to be statistically significant. Analyses were performed using STATA software (release 12, STATA Corp, College Station, TX). Two GPX1 SNPs were associated with advanced (stage III/IV) PCa risk ( Table 1) . For GPX1 rs17650792, hazard ratios for AA, AG, and GG were 1.00 (referent), 1.14 (95% confidence interval [CI] = 0.95 to 1.37), and 1.29 (95% CI = 1.01 to 1.63; P trend = .03). For GPX1 rs1800668, hazard ratios for CC, CT, and TT were 1.00 (referent), 0.81 (95% CI = 0.68 to 0.96), and 0.73 (95% CI = 0.54 to 0.97; P trend = .005). The hazard ratios were similar for stage IV PCa. SEPP1 SNPs were not associated with stage III/IV PCa risk, but SEPP1 rs7579 was associated with stage IV PCa risk, with hazard ratios for GG, AG, and AA of 1.00 (referent), 0.81 (95% CI = 0.66 to 0.99), and 0.71 (95% CI = 0.51 to 1.00; P trend = .01). Higher toenail selenium levels were associated with a reduced risk of advanced PCa in all genotype subgroups ( Table 2 ). None of the tested multiplicative interactions between genotype and selenium status were statistically significant. Results were comparable for stage IV PCa (data not shown).
In this long-term prospective analysis of advanced PCa, we observed no statistical interactions between toenail selenium levels and SEPP1 and GPX1 genetic variants. Studies investigating the effect of selenium on (advanced) PCa incidence have had mixed results (2, 4, 5, 12) . Our results indicate that it is unlikely that these disparate findings are the result of differences in SEPP1 and GPX1 variation. We showed that higher toenail selenium levels were associated with a decreased risk of advanced PCa in all genotype subgroups.
We observed SEPP1 and GPX1 variant main effects on advanced (stage III/IV or IV) PCa risk ( Table 1) . These are mostly novel findings (7, 9, 22) . GPX1 rs1800668 is in high linkage disequilibrium with rs1050450 (r 2 = 0.9), which resides in the coding region, results in an amino acid substitution of proline with leucine (23, 24) , and may, therefore, be the true functional polymorphism.
Strengths of our study include the prospective design and large number of advanced, clinically relevant PCa cases. We comprehensively investigated all common variation in SEPP1 and GPX1 using a tagging SNP approach. A possible limitation of our study is that we had no repeated exposure measurements during follow-up.
In conclusion, our data show that low selenium is associated with an increased risk of advanced PCa, independently of common genetic variation in SEPP1 and GPX1. Specific SEPP1 and GPX1 variants may, however, have a main effect on advanced PCa risk. The null findings of prior studies of selenium and PCa may at least partially be explained by the possibility that additional selenium intake only benefits men with relatively low selenium levels and not those who are selenium replete (6, 7, 12) .
